The OTC business division of Ranbaxy Laboratories, Ranbaxy Global Consumer Healthcare (RGCH) has launched “Volini Duo”, India’s first approved two-in-one pain killer, a unique bi-layered acetaminophen tablet, specially formulated to give dual pain relief. The product has been introduced pan India.


Commenting on the launch of the product, Brijesh Kapil, vice president, RGCH, said, “Ranbaxy remains committed to developing and offering quality, safe, efficacious and innovative solutions to consumers. The introduction of ‘Volini Duo’ is a move in this direction.”


‘Volini Duo’ has been developed by scientists at Ranbaxy’s state-of-the-art R&D centre in Gurgaon, using advanced Matrix technology, which enables the regulated release of the medicine in the gastrointestinal tract. It is specifically effective for back & joint pains, which are primarily chronic in nature. Unlike regular pain killers which give relief for upto four hours, Volini Duo with its unique matrix formulation, provides relief for double the duration of around 8 hours. The product has a high safety profile making it ideal for mass use.


Volini Duo tablet marks the entry of Ranbaxy in the OTC oral pain reliever category. The OTC oral analgesics market in India is estimated to be Rs.700 crore and is growing annually at a rate of 10.5 per cent. Globally acetaminophen happens to be the highest selling molecule in the OTC pain reliever category. Due to today’s fast paced lifestyle and lack of exercise, there is an increasing incidence of back pain, joint pain, body aches and muscular sprains.


Ranbaxy Global Consumer Healthcare (RGCH) was established in October 2002 with an objective to promote OTC healthcare brands to consumers. Today it has some of the top selling brands with leadership status in its segment. The division has over 15 products in its basket, including extensions. The major brands from RGCH include Revital, Volini (pain relieving gel & spray), Chericof (cough syrup), Pepfiz (digestive).